Characteristics of patients with lung cancer in clinical practice and their potential eligibility for clinical trials evaluating tyrosine kinase inhibitors or immune checkpoint inhibitors
Introduction: In- and exclusion criteria of randomized clinical trials (RCTs) aim to include a homogeneous study-population. This study compared characteristics of lung cancer patients from phase III RCTs evaluating tyrosine kinase inhibitors (TKIs) or immune checkpoint inhibitors (ICIs) with charac...
Main Authors: | Abtahi, S. (Author), Croes, S. (Author), de Vries, F. (Author), Dingemans, A.-M.C (Author), Driessen, J.H.M (Author), Klungel, O.H (Author), Souverein, P. (Author), van Geel, R. (Author), van Veelen, A. (Author) |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier Ltd
2022
|
Subjects: | |
Online Access: | View Fulltext in Publisher |
Similar Items
-
Clinical diagnosis and treatment of immune checkpoint inhibitor‐associated pneumonitis
by: Hanping Wang, et al.
Published: (2020-01-01) -
The use of UK primary care databases in health technology assessments carried out by the National Institute for health and care excellence (NICE)
by: Thomas P. Leahy, et al.
Published: (2020-07-01) -
Clinical Diagnosis and Treatment Recommendations for the Pneumonitis Associated with Immune Checkpoint Inhibitor
by: Hanping WANG, et al.
Published: (2019-10-01) -
Validation of autism spectrum disorder diagnoses recorded in the Clinical Practice Research Datalink, 1990–2014
by: Hagberg KW, et al.
Published: (2017-09-01) -
Clinical Trials of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
by: Anne Dyhl-Polk, et al.
Published: (2021-06-01)